VTRS Earnings Prediction
The chart below shows how VTRS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VTRS sees a +0.61% change in stock price 10 days leading up to the earnings, and a -0.31% change 10 days following the report. On the earnings day itself, the stock moves by +0.11%. This data can give you a slight idea of what to expect for the next quarter's release.
VTRS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
3.75B
-4.84%
-1.20%
Gross Margin
42.81%
-2.53%
1.90%
Operating Margin
14.38%
-4.07%
13.86%
Net Margin
2.53%
-69.92%
-129.42%
EPS
0.08
-70.37%
-129.63%
No Data Available
VTRS Earnings Analysis
Viatris Inc. Common Stock Corporation (VTRS.O) Earnings Conference Call
Positive
Revenue Growth Performance: 1. Strong Revenue Growth: Viatris reported total revenues of $3.8 billion for Q3 2024, reflecting an operational revenue growth of approximately 3% year-over-year.
Adjusted EBITDA Growth: 2. Increased Adjusted EBITDA: The company achieved an adjusted EBITDA of $1.3 billion, which represents a growth of approximately 4% compared to the previous year.
Adjusted EPS Growth: 3. Rising Adjusted EPS: Adjusted earnings per share increased to $0.75, marking a growth of approximately 6% from the prior year.
Strong Free Cash Flow: 4. Significant Free Cash Flow: Viatris generated free cash flow of $866 million in the quarter, excluding transaction costs and taxes, demonstrating strong cash generation capabilities.
Debt Reduction Strategy: 5. Debt Repayment Progress: The company repaid approximately $1.9 billion in debt, positioning itself firmly on track to achieve its long-term gross leverage target.
Negative
Brand Sales Decline: 1. Declining Brand Sales: Net sales in the brand segment declined due to the continued impact of Medicaid utilization in certain non-promoted brands and lower EpiPen volumes, which were affected by formulary changes earlier in the year.
Revenue Growth Slowdown: 2. Lower Expected Revenue: The company reaffirmed its outlook for full year 2024 base business operational revenue growth of approximately 2%, indicating a slowdown compared to previous growth rates.
Fourth Quarter Revenue Decline: 3. Fourth Quarter Revenue Decline: Total revenue is expected to be lower in the fourth quarter due to normal product seasonality in developed markets and phasing of certain generic products in North America.
Operating Expenses Impact: 4. Increased Operating Expenses: Adjusted EBITDA and adjusted earnings per share will be impacted by a step down in adjusted gross margin and an increase in adjusted SG&A due to timing and normal cadence of investment.
ARV Supply Chain Challenges: 5. ARV Supply Chain Issues: The company continues to face supply chain impacts affecting its ARV generics business, which have been a drag on performance and are expected to persist until backlogs are resolved.
VTRS FAQs
How does VTRS typically perform around its earnings report dates?
Is Viatris Inc. (VTRS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VTRS Earning Call Sentiment
Viatris Inc. (VTRS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
VTRS.O
-0.09%Positive
The earnings call presents a mixed outlook: stable financial performance with slight growth in revenue, EBITDA, and EPS, alongside successful debt reduction. However, concerns arise from lower Q4 revenue expectations, supply chain challenges, and competitive pressures. Positive elements include a promising share buyback program and consistent new product revenue. The Q&A section reveals cautious management responses, indicating uncertainty. Overall, the sentiment leans neutral, reflecting balanced risks and opportunities without significant catalysts for strong stock price movement.
